{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:35Z","timestamp":1790797115793,"version":"4.1.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    The morbidity and mortality of hepatic fibrosis caused by various etiologies are high worldwide, and the trend is increasing annually. At present, there is no effective method to cure hepatic fibrosis except liver transplantation, and its serious complications threaten the health of patients and cause serious medical burdens. Additionally, there is no specific drug for the treatment of hepatic fibrosis, and many drugs with anti-hepatic fibrosis effects are in the research and development stage. Recently, remarkable progress has been made in the research and development of anti-hepatic fibrosis drugs targeting different targets. We searched websites such as PubMed, ScienceDirect, and\n                    <jats:ext-link>Home-ClinicalTrials.gov<\/jats:ext-link>\n                    and found approximately 120 drugs with anti-fibrosis properties, some of which are in phase \u2161 or \u2162 clinical trials. Additionally, although these drugs are effective against hepatic fibrosis in animal models, most clinical trials have shown poor results, mainly because animal models do not capture the complexity of human hepatic fibrosis. Besides, the effect of natural products on hepatic fibrosis has not been widely recognized at home and abroad. Furthermore, drugs targeting a single anti-hepatic fibrosis target are prone to adverse reactions. Therefore, currently, the treatment of hepatic fibrosis requires a combination of drugs that target multiple targets. Ten new drugs with potential for development against hepatic fibrosis were selected and highlighted in this mini-review, which provides a reference for clinical drug use.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.874408","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T01:14:37Z","timestamp":1655082877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":80,"title":["New Drugs for Hepatic Fibrosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Liang","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lfs.2018.05.048","article-title":"Targeting Keap-1\/Nrf-2 Pathway and Cytoglobin as a Potential Protective Mechanism of Diosmin and Pentoxifylline against Cholestatic Liver Cirrhosis","volume":"207","author":"Ali","year":"2018","journal-title":"Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CPAA.S276085","article-title":"Clinical Impact of Liraglutide as a Treatment of Obesity","volume":"13","author":"Alruwaili","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12072-019-09970-3","article-title":"Reversal of NASH Fibrosis with Pharmacotherapy","volume":"13","author":"Alukal","year":"2019","journal-title":"Hepatol. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic Acid and INT-767 Modulate Collagen Deposition in a NASH In Vitro Model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the Treatment of Liver Fibrosis in Adults with Nonalcoholic Steatohepatitis: AURORA Phase 3 Study Design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/gut.2006.107136","article-title":"A Pilot Study in Patients with Established Advanced Liver Fibrosis Using Pirfenidone","volume":"55","author":"Armendariz-Borunda","year":"2006","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide Safety and Efficacy in Patients with Non-alcoholic Steatohepatitis (LEAN): a Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(15)61199-0","article-title":"Trials of Obeticholic Acid for Non-alcoholic Steatohepatitis","volume":"386","author":"Armstrong","year":"2015","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1136\/gutjnl-2015-309861.1610.1016\/s0168-8278(15)30002-7","article-title":"G01 : Liraglutide Is Effective in the Histological Clearance of Non-alcoholic Steatohepatitis in a Multicentre, Doubleblinded, Randomised, Placebo-Controlled Phase II Trial","volume":"62","author":"Armstrong","year":"2015","journal-title":"J. Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12876-019-1149-z","article-title":"Validity of Biopsy-Based Drug Effects in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed NASH","volume":"19","author":"Baandrup Kristiansen","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-alcoholic Steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/hep.30684","article-title":"Acute Liver Failure during Pirfenidone Treatment Triggered by Co-medication with Esomeprazole","volume":"70","author":"Benesic","year":"2019","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH Drug Development Hitches a Lift on PPAR Agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Portal Hypertension and Hepatic Fibrosis in Experimental Advanced Chronic Liver Disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"154113","DOI":"10.1016\/j.metabol.2019.12.059","article-title":"A 3-week Nonalcoholic Steatohepatitis Mouse Model Allows the Rapid Evaluation of Liraglutide and Elafibranor Benefits on NASH","volume":"104","author":"Briand","year":"2020","journal-title":"Metabolism"},{"key":"B16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Improvements in Histologic Features and Diagnosis Associated with Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results from the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/S0168-8278(18)30420-3","article-title":"A Multicenter, Randomized, Double-Blind, Plb-Controlled Trial of Galectin-3 Inhibitor (Gr-md-02) in Patients with Nash Cirrhosis and Portal Hypertension","volume":"68","author":"Chalasani","year":"2018","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jhep.2020.11.016","article-title":"Targeting Nestin+ Hepatic Stellate Cells Ameliorates Liver Fibrosis by Facilitating T\u03b2RI Degradation","volume":"74","author":"Chen","year":"2021","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential Effects of Sorafenib on Liver versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha\/C-X-C Receptor Type 4 axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/13543780903501539","article-title":"Pirfenidone: an Anti-fibrotic Therapy for Progressive Kidney Disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1016\/S0618-8278(19)31070-9","article-title":"Fri-329-comparison of Seladelpar and Combinations with Liraglutide or Selonsertib for Improvement of Fibrosis and NASH in a Diet-Induced and Biopsy-Confirmed Mouse Model of Nash","volume":"70","author":"Choi","year":"2019","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0168-8278(03)80311-2","article-title":"Mechanism of Pentoxifylline Action on Liver Fibrosis","volume":"38","author":"Chooklin","year":"2003","journal-title":"J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","article-title":"STAT3-mediated Attenuation of CCl4-Induced Mouse Liver Fibrosis by the Protein Kinase Inhibitor Sorafenib","volume":"46","author":"Deng","year":"2013","journal-title":"J. Autoimmun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0168-8278(99)80192-5","article-title":"Effect of Pentoxifylline on Early Proliferation and Phenotypic Modulation of Fibrogenic Cells in Two Rat Models of Liver Fibrosis and on Cultured Hepatic Stellate Cells","volume":"30","author":"Desmouli\u00e8re","year":"1999","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/s0168-8278(02)00245-3","article-title":"Effect of Pirfenidone on Rat Hepatic Stellate Cell Proliferation and Collagen Production","volume":"37","author":"Di Sario","year":"2002","journal-title":"J. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","article-title":"Obeticholic Acid: towards First Approval for NASH","volume":"394","author":"Eslam","year":"2019","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","article-title":"Emerging Therapeutic Targets for the Treatment of Hepatic Fibrosis","volume":"21","author":"Fagone","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular Therapies for HCC: Looking outside the Box","volume":"72","author":"Faivre","year":"2020","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/hep.30309","article-title":"Is This the Last Requiem for Simtuzumab","volume":"69","author":"Fickert","year":"2019","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan Improves Liver Function in Patients with Cirrhosis and High Model for End-Stage Liver Disease Scores Compared with Placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and Safety Study of Cenicriviroc for the Treatment of Non-alcoholic Steatohepatitis in Adult Subjects with Liver Fibrosis: CENTAUR Phase 2b Study Design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(16)30734-6","article-title":"Liraglutide for Patients with Non-alcoholic Steatohepatitis","volume":"387","author":"Gaborit","year":"2016","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0168-8278(02)00272-6","article-title":"Pirfenidone Effectively Reverses Experimental Liver Fibrosis","volume":"37","author":"Garc\u00eda","year":"2002","journal-title":"J. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized Placebo-Controlled Trial of Emricasan for Non-alcoholic Steatohepatitis-Related Cirrhosis with Severe Portal Hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/hep4.1439","article-title":"A Pilot Genome-wide Analysis Study Identifies Loci Associated with Response to Obeticholic Acid in Patients with NASH","volume":"3","author":"Gawrieh","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jhep.2021.02.012","article-title":"Targeting Cell-Intrinsic Metabolism for Antifibrotic Therapy","volume":"74","author":"Gilgenkrantz","year":"2021","journal-title":"J. Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"G336","DOI":"10.1152\/ajpgi.0020910.1152\/ajpgi.00209.2019","article-title":"Investigating Fibrosis and Inflammation in an Ex Vivo NASH Murine Model","volume":"318","author":"Gore","year":"20202019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep4.1360","article-title":"Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats through a Hepatocyte-Mediated Paracrine Mechanism","volume":"3","author":"Gracia-Sancho","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1440-1681.2009.05262.x","article-title":"Pirfenidone: a Potential Therapeutic Option in the Treatment of Liver Fibrosis","volume":"36","author":"Grizzi","year":"2009","journal-title":"Clin. Exp. Pharmacol. P"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/hep.31177","article-title":"New Drugs for NASH and HIV Infection: Great Expectations for a Great Need","volume":"71","author":"Guaraldi","year":"2020","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0203054","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and Variability of Three Non-invasive Liver Fibrosis Imaging Modalities to Evaluate Efficacy of GR-MD-02 in Subjects with NASH and Bridging Fibrosis during a Phase-2 Randomized Clinical Trial","volume":"13","author":"Harrison","year":"","journal-title":"PloS one"},{"key":"B48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A Randomized, Placebo-Controlled Trial of Emricasan in Patients with NASH and F1-F3 Fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised Clinical Study: GR-MD-02, a Galectin-3 Inhibitor, vs. Placebo in Patients Having Non-alcoholic Steatohepatitis with Advanced Fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharm. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41575-020-0264-1","article-title":"Obeticholic Acid for the Treatment of NASH","volume":"17","author":"Hindson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 Ablation Protects Mice from Diet-Induced NASH: a Major Scavenging Role for Galectin-3 in Liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J. Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"Glucagon-like Peptide-1 Analogue, Liraglutide, Improves Liver Fibrosis Markers in Obese Women with Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease","volume":"81","author":"Kahal","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep4.1160","article-title":"Prolonged Cenicriviroc Therapy Reduces Hepatic Fibrosis Despite Steatohepatitis in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis","volume":"2","author":"Kruger","year":"2018","journal-title":"Hepatol. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1053\/j.gastro.2010.01.040","article-title":"Pentoxifylline Does Not Decrease Short-Term Mortality but Does Reduce Complications in Patients with Advanced Cirrhosis","volume":"138","author":"Lebrec","year":"2010","journal-title":"Gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/cts.12397","article-title":"Pharmacokinetics, Safety, and CCR2\/CCR5 Antagonist Activity of Cenicriviroc in Participants with Mild or Moderate Hepatic Impairment","volume":"9","author":"Lefebvre","year":"","journal-title":"Clin. Transl. Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis","volume":"11","author":"Lefebvre","year":"","journal-title":"PloS one"},{"key":"B57","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","article-title":"Development and Characterization of Sorafenib-Loaded PLGA Nanoparticles for the Systemic Treatment of Liver Fibrosis","volume":"221","author":"Lin","year":"2016","journal-title":"J. Control Release"},{"key":"B58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/hep.29513","article-title":"A Multifunctional Nanocarrier for Efficient TRAIL-Based Gene Therapy against Hepatocellular Carcinoma with Desmoplasia in Mice","volume":"67","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jhep.2007.10.010","article-title":"Early Switch to Pentoxifylline in Patients with Severe Alcoholic Hepatitis Is Inefficient in Non-responders to Corticosteroids","volume":"48","author":"Louvet","year":"2008","journal-title":"J. Hepatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.biopha.2017.01.107","article-title":"Sorafenib: A Potential Therapeutic Drug for Hepatic Fibrosis and its Outcomes","volume":"88","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: a Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/liv.13177","article-title":"Simtuzumab Treatment of Advanced Liver Fibrosis in HIV and HCV-Infected Adults: Results of a 6-month Open-Label Safety Trial","volume":"36","author":"Meissner","year":"2016","journal-title":"Liver Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results with Insights on the Natural History of the Disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic Landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/s0168-8278(97)80473-4","article-title":"Effects of Simvastatin, Pentoxifylline and Spironolactone on Hepatic Fibrosis and Portal Hypertension in Rats with Bile Duct Ligation","volume":"26","author":"Oberti","year":"1997","journal-title":"J. Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhep.2014.05.014","article-title":"Pentoxifylline vs. Corticosteroid to Treat Severe Alcoholic Hepatitis: a Randomised, Non-inferiority, Open Trial","volume":"61","author":"Park","year":"2014","journal-title":"J. Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A Randomized, Double-Blind, Multicenter, Phase 2b Study to Evaluate the Safety and Efficacy of a Combination of Tropifexor and Cenicriviroc in Patients with Nonalcoholic Steatohepatitis and Liver Fibrosis: Study Design of the TANDEM Trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"B68","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0270-9139(93)90062-r","article-title":"Pentoxifylline Prevents Fibrosis in an Animal Model and Inhibits Platelet-Derived Growth Factor-Driven Proliferation of Fibroblasts","volume":"17","author":"Peterson","year":"1993","journal-title":"Hepatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1476-5381.1996.tb16012.x","article-title":"Inhibition by Pentoxifylline of Extracellular Signal-Regulated Kinase Activation by Platelet-Derived Growth Factor in Hepatic Stellate Cells","volume":"119","author":"Pinzani","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","article-title":"Efficacy of Simtuzumab versus Placebo in Patients with Idiopathic Pulmonary Fibrosis: a Randomised, Double-Blind, Controlled, Phase 2 Trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12072-019-10001-4","article-title":"New Drugs for NAFLD: Lessons from Basic Models to the Clinic","volume":"14","author":"Reimer","year":"2020","journal-title":"Hepatol. Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","first-page":"9046","DOI":"10.1038\/s41598-019-45178-z","article-title":"Combined Obeticholic Acid and Elafibranor Treatment Promotes Additive Liver Histological Improvements in a Diet-Induced Ob\/ob Mouse Model of Biopsy-Confirmed NASH","volume":"9","author":"Roth","year":"2019","journal-title":"Sci. Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and Upcoming Pharmacotherapy for Non-alcoholic Fatty Liver Disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"B76","doi-asserted-by":"publisher","first-page":"116982","DOI":"10.1016\/j.lfs.2019.116982","article-title":"Pirfenidone Alleviates Concanavalin A-Induced Liver Fibrosis in Mice","volume":"239","author":"Salah","year":"2019","journal-title":"Life Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep4.1474","article-title":"Pirfenidone Is an Agonistic Ligand for PPAR\u03b1 and Improves NASH by Activation of SIRT1\/LKB1\/pAMPK","volume":"4","author":"Sandoval-Rodriguez","year":"2020","journal-title":"Hepatol. Commun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1440-1746.2006.04756.x","article-title":"Beneficial Effects of Pentoxifylline on Hepatic Steatosis, Fibrosis and Necroinflammation in Patients with Non-alcoholic Steatohepatitis","volume":"22","author":"Satapathy","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver Fibrosis: Direct Antifibrotic Agents and Targeted Therapies","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/1751-2980.12967","article-title":"Efficacy and Safety of Drugs for Nonalcoholic Steatohepatitis","volume":"22","author":"Shen","year":"2021","journal-title":"J. Dig. Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt10.1111\/apt.15030","article-title":"Randomised Clinical Trial: Emricasan versus Placebo Significantly Decreases ALT and Caspase 3\/7 Activation in Subjects with Non-alcoholic Fatty Liver Disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment. Pharm. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Non-alcoholic Steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"105315","DOI":"10.1016\/j.tiv.2022.105315","article-title":"Hepatic Stellate Cell Activation by TGF\u03b2 Induces Hedgehog Signaling and Endoplasmic Reticulum Stress Simultaneously","volume":"80","author":"Solhi","year":"2022","journal-title":"Toxicol Vitro"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/hepr.13425","article-title":"Phase 3 Drug Pipelines in the Treatment of Non-alcoholic Steatohepatitis","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and Future Pharmacological Therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined Delivery of Sorafenib and a MEK Inhibitor Using CXCR4-Targeted Nanoparticles Reduces Hepatic Fibrosis and Prevents Tumor Development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep.24427","article-title":"Complementary Vascular and Matrix Regulatory Pathways Underlie the Beneficial Mechanism of Action of Sorafenib in Liver Fibrosis","volume":"54","author":"Thabut","year":"2011","journal-title":"Hepatology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.2147\/IJN.S171280","article-title":"CXCR4-targeted Liposomal Mediated Co-delivery of Pirfenidone and AMD3100 for the Treatment of TGF\u03b2-Induced HSC-T6 Cells Activation","volume":"14","author":"Ullah","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/hep4.1133","article-title":"Drug Idiosyncrasy Due to Pirfenidone Presenting as Acute Liver Failure: Case Report and Mini-Review of the Literature","volume":"2","author":"Verma","year":"2017","journal-title":"Hepatol. Commun."},{"key":"B91","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejphar.2007.06.039","article-title":"Effect of Fetuin, a TGFbeta Antagonist and Pentoxifylline, a Cytokine Antagonist on Hepatic Stellate Cell Function and Fibrotic Parameters in Fibrosis","volume":"572","author":"Verma-Gandhu","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/DDDT10.2147\/DDDT.S289016","article-title":"Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects under Fasting and Fed Conditions","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic Acid for the Treatment of Non-alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/hep.25778","article-title":"Pentoxifylline Decreases Oxidized Lipid Products in Nonalcoholic Steatohepatitis: New Evidence on the Potential Therapeutic Mechanism","volume":"56","author":"Zein","year":"2012","journal-title":"Hepatology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/his.13745","article-title":"Histopathological and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib","volume":"74","author":"Zhang","year":"2019","journal-title":"Histopathology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bpg.2017.04.005","article-title":"Reversal of Liver Fibrosis: From Fiction to Reality","volume":"31","author":"Zoubek","year":"2017","journal-title":"Best. Pract. Res. Clin. Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.874408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T01:14:41Z","timestamp":1655082881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.874408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":97,"alternative-id":["10.3389\/fphar.2022.874408"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.874408","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"article-number":"874408"}}